Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial-Reference-Cited by-同舟云学术

Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

Published:2018-05 Issue:5 Volume:20 Page:1148-1155
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Mathieu Chantal¹^ORCID,Bode Bruce W.²,Franek Edward³,Philis‐Tsimikas Athena⁴,Rose Ludger⁵,Graungaard Tina⁶,Birk Østerskov Anne⁷,Russell‐Jones David⁸

Affiliation:

1. Clinical and Experimental EndocrinologyUniversity Hospital Leuven Leuven Belgium

2. Atlanta Diabetes Associates Atlanta Georgia

3. Mossakowski Clinical Research Centre, Polish Academy of Sciences Warsaw Poland

4. Scripps Whittier Diabetes Institute, Scripps Health San Diego California

5. Institute of Diabetes Research Münster Germany

6. Biostatistics Aalborg 2, Novo Nordisk A/S Aalborg Denmark

7. Medical & Science, Insulin & Digital Health, Novo Nordisk A/S Søborg Denmark

8. Diabetes and EndocrinologyRoyal Surrey County Hospital and University of Surrey Guildford UK

Funder

Novo Nordisk A/S

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13205

Reference25 articles.

1. Glycaemic targets;American Diabetes Association;Diabetes Care,2016

2. Guideline for management of postmeal glucose in diabetes

3. Premeal Injection of Rapid-Acting Insulin Reduces Postprandial Glycemic Excursions in Type 1 Diabetes

4. Insulin analogues in type 1 diabetes mellitus: getting better all the time

5. Sanofi‐Aventis. Apidra Summary of Product Characteristics.2009.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000557/WC500025250.pdf. Accessed July 21 2017.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultrafast-acting insulin: pharmacological properties and their impact on clinical aspects;Meditsinskiy sovet = Medical Council;2024-09-02

2. Are New Ultra-Rapid-Acting Insulins Associated with Improved Glycemic Control and Reduced Hypoglycemia in Comparison to Conventional Rapid-Acting Insulins for Individuals with Type 1 and Type 2 Diabetes? A Systematic Review and Meta-Analysis;Diabetes Technology & Therapeutics;2024-08-01

3. 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association;Diabetes & Metabolism Journal;2024-07-31

4. Analogues ultra-rapides de l’insuline et délivrance automatisée de l’insuline, un réel pas en avant ?;Médecine des Maladies Métaboliques;2024-06

5. News in insulin treatment;Vnitřní lékařství;2024-02-26